Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: importance of hepatic lipogenesis.
Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: importance of hepatic lipogenesis.
复制标题
作者：
Sato A;Kawano H;Notsu T;Ohta M;Nakakuki M;Mizuguchi K;Itoh M;Suganami T;Ogawa Y
鉴于二十碳五烯酸（EPA）的多效性，了解EPA是否能够改善肥胖是很有趣的。在这里，我们研究了EPA在两种不同肥胖模型小鼠中的抗肥胖作用。雄性C57 BL/6 J小鼠喂食高脂/高蔗糖饲料（25.0% [w/w]脂肪，32.5% [w/w]蔗糖）（HF/HS组）或高脂饲料（38.1% [w/w]脂肪，8.5% [w/w]蔗糖）（HF组）4-20周。在HF/HS + EPA和HF + EPA组中，通过用EPA部分替代脂肪来施用总共5%的EPA。HF/HS组和HF组同样发生肥胖。EPA处理强烈抑制HF/HS喂养小鼠（HF/HS + EPA组）的体重增加和肥胖相关的高血糖症和高胰岛素血症，其中肝脏甘油三酯含量和脂肪生成酶增加。EPA对HF喂养的小鼠（HF + EPA组）的体重没有明显的影响，而肝脂肪生成酶的表达没有增强。此外，EPA能够减少HF/HS组的肝脏甘油三酯分泌并改变VLDL脂肪酸组成。通过间接量热分析，我们还发现EPA能够增加HF/HS + EPA组的能耗。本研究首次证明EPA在HF/HS诱导的肥胖中的抗肥胖作用与抑制肝脏脂肪生成和脂肪变性相关。由于代谢综合征通常与肝脏脂肪生成和脂肪变性有关，因此数据表明EPA适合于治疗代谢综合征。
Given the pleiotropic effect of eicosapentaenoic acid (EPA), it is interesting to know whether EPA is capable of improving obesity. Here we examined the anti-obesity effect of EPA in mice with two distinct models of obesity. Male C57BL/6J mice were fed a high-fat/high-sucrose diet (25.0% [w/w] fat, 32.5% [w/w] sucrose) (HF/HS group) or a high-fat diet (38.1% [w/w] fat, 8.5% [w/w] sucrose) (HF group) for 4–20 weeks. A total of 5% EPA was administered by partially substituting EPA for fat in the HF/HS + EPA and HF + EPA groups. Both the HF/HS and HF groups similarly developed obesity. EPA treatment strongly suppresses body weight gain and obesity-related hyperglycemia and hyperinsulinemia in HF/HS-fed mice (HF/HS + EPA group), where hepatic triglyceride content and lipogenic enzymes are increased. There is no appreciable effect of EPA on body weight in HF-fed mice (HF + EPA group) without enhanced expression of hepatic lipogenic enzymes. Moreover, EPA is capable of reducing hepatic triglyceride secretion and changing VLDL fatty acid composition in the HF/HS group. By indirect calorimetry analysis, we also found that EPA is capable of increasing energy consumption in the HF/HS + EPA group. This study is the first demonstration that the anti-obesity effect of EPA in HF/HS-induced obesity is associated with the suppression of hepatic lipogenesis and steatosis. Because the metabolic syndrome is often associated with hepatic lipogenesis and steatosis, the data suggest that EPA is suited for treatment of the metabolic syndrome.
登录
查看更多内容
影响因子：
7.7
作者：
Molero, JC;Waring, SG;James, DE
通讯作者：
James, DE
影响因子：
8.7
作者：
Goudriaan, JR;Tacken, PJ;Jong, MC
通讯作者：
Jong, MC
影响因子：
7.7
作者：
Marchesini, G;Brizi, M;Melchionda, N
通讯作者：
Melchionda, N
影响因子：
4.8
作者：
Hannah, VC;Ou, JF;Brown, MS
通讯作者：
Brown, MS
影响因子：
8.2
作者：
Kuda, O.;Jelenik, T.;Kopecky, J.
通讯作者：
Kopecky, J.